An investigational vaccine that targets common KRAS mutations induced durable immune responses among individuals at high risk for pancreatic cancer, results of a phase 1 clinical trial showed.Eighteen of 20 participants achieved KRAS-specific T-cell responses. Several individuals had either complete radiographic resolution or regression of pancreatic cysts, and none developed pancreatic cancer by data cutoff.The vaccine also appeared safe, according…
Source: Healio News
